

NIH funding opportunities

4 September 2024 (#25)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

NOT-HL-24-027 Notice of Intent to Publish a Funding Opportunity Announcement for Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional). The National Heart, Lung and Blood Institute (NHLBI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) which will support a consortium to phenotype 0-2 year old children with severe viral lower respiratory tract infections (LRTI) with follow up until pre-school age for pulmonary sequelae. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop responsive projects. The NOFOs are expected to be published in January 2025 with an anticipated application receipt date in June 2025.

NOT-OD-24-163 NIH's Adoption of Common Forms for Biographical Sketch and Current and Pending (Other) Support by **May 25, 2025 for **Applications and Research Performance Progress Reports (RPPRs)**.** The Common Forms represent a collaborative effort between federal research agencies to ensure standard disclosure requirements. in accordance with NIH's Peer Review Regulations at [42 Code of Federal Regulations Part 52h](#), NIH currently plans to continue collecting three required agency specific data elements (i.e., Personal Statement, Contributions to Science, and Honors) to assess qualifications. **These data elements will be collected separately from the Common Forms on a new NIH Biographical Sketch Supplement.**

Biographical Sketch

- NIH will no longer accept the NIH Biographical Sketch format page.
- NIH will require the use of the Common Form for Biographical Sketch.
- NIH will require the use of a new NIH Biographical Sketch Supplement to collect the "Personal Statement," "Contributions to Science," and "Honors" statements.
- All Biosketches must be prepared on <https://www.ncbi.nlm.nih.gov/sciencv/>

Current and Pending (Other) Support

- NIH will no longer accept the NIH Other Support format page.
- NIH will require the use of the Common Form for Current and Pending (Other) Support.

Failure to use the required forms or format pages may cause NIH to withdraw your application from consideration.

[NOT-OD-24-086](#) **New NIH "FORMS-I" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2025.** All active [Parent](#) and IC-issued NOFOs with due dates on or after January 25, 2025, will be reissued or updated to add FORMS-I application packages.

Parent Announcements

[NOT-OD-24-099](#) **Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates **Modified Expiration Date: January 8, 2025**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

[NOT-DK-24-029](#) **Analysis of Existing Linked Datasets to Understand the Relationship between Housing Program Participation and Risk for Chronic Diseases and Other Conditions (R01-Clinical Trial Not Allowed).** This NOSI expresses the interest of the participating Institutes and Offices in the evaluation of the effects of housing program participation on risk for chronic diseases and conditions within the missions of the participating Institutes and Offices. Housing programs or policies of interest may be supported by federal, state, or local-level agencies or organizations. Applications in response to this NOSI must propose to evaluate existing datasets with housing program participation data that can be administratively linked to health outcome data. Projects that propose to evaluate longitudinal health outcomes are particularly encouraged. This notice applies to due dates on or after October 7, 2024, and subsequent receipt dates through September 8, 2027.

Notice of Funding Opportunity (NOFO)

[RFA-AG-25-019](#) **The Impact of Stressors on the Biological Mechanisms of Aging and Other Aging-Associated Outcomes in Experimental Model Systems (R61/R33 Clinical Trial Not allowed).** This notice of funding opportunity (NOFO) invites [R61/R33](#) applications proposing research that incorporates exposures to a stressor(s) during the post-development period ("adulthood") into studies of aging processes. Research proposed in the initial, exploratory (R61) phase will seek to determine whether exposure to a stressor(s) (e.g., physical, social, and/or environmental stressors of well-defined duration, intensity, and timing) during adulthood results in measurable changes in one or more of the hallmarks of aging. The second, developmental (R33) phase will then expand upon findings yielded in the R61 phase to determine the impacts of the stressor(s) on lifespan, healthspan, resilience, and/or interactions with other "input variables" such as genotype, diet, interventions, etc. Applicants can propose to employ in vitro systems; laboratory animals; or well-characterized wild, captive, free-ranging, or domesticated animal populations. Funded projects will receive up to two years of R61 support and may also receive up to three years of R33 support (contingent upon NIA's determination of the success in achieving R61 milestones, NIA priorities, and availability of funds).

Date: November 07, 2024. All applications are due by 5:00 PM local time of applicant organization.

Budget: For the R61 phase, NIA intends to commit \$3.25 million in FY 2025 to fund 8 awards. For the R61 exploratory phase, the combined budget for direct costs for the two-year project period may not exceed \$500,000, with no more than \$250,000 requested in any single year. For the three-year R33 implementation phase, applicants' combined budget for direct costs may not exceed \$1,500,000, with no more than \$500,000 requested in any single year. The maximum project period for the R61 exploratory phase is two years. The maximum project period for the R33 implementation phase is three years.

[RFA-AG-25-030](#) Understanding the mechanisms underlying the age-related changes in gait biomechanics and the impact on the increased metabolic cost of walking (R01 Clinical Trial Optional). The National Institute on Aging (NIA) invites R01 applications that propose human studies to better understand the mechanisms underlying compensatory gait, posture, and molecular changes that contribute to slower walking speed and increased metabolic cost of walking. This Notice of Funding Opportunity (NOFO) encourages interdisciplinary collaborations to design integrative approaches that explore interactions among multiple systems (e.g., skeletal, muscle, tendon, somatosensory, and central nervous). This NOFO also encourages innovative approaches such as computational modeling, imaging and sensor technologies, machine learning, and artificial intelligence to disentangle compensatory gait alterations with aging that contribute to increased metabolic cost of walking and fatigue. Areas of interest include: 1) mechanisms and effects of central nervous system changes; 2) neuromuscular changes; 3) skeletal muscle bioenergetics; 4) computational modeling and simulation; and 5) changes in tissue structure and function (e.g., muscle-tendon complex, extracellular matrix).

Date: November 07, 2024. All applications are due by 5:00 PM local time of applicant organization.

Budget: NIA intends to commit \$3,000,000 in fiscal year 2025 to fund up to 4 awards. Application budgets should reflect the actual needs of the proposed project and cannot exceed \$500,000 per year in direct costs. The maximum project period is 5 years.

[RFA-AI-24-057](#) Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed). This purpose of this notice of funding opportunity (NOFO) is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies.

Date: December 04, 2024. All applications are due by 5:00 PM local time of applicant organization.

Budget: NIAID intends to commit \$1.2 M in FY 2025 to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

[RFA-AI-24-064](#) Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed). This purpose of this notice of funding opportunity (NOFO) is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies.

Date: December 04, 2024. All applications are due by 5:00 PM local time of applicant organization.

Budget: NIAID intends to commit \$0.8 M in FY 2025 to fund 2-3 awards. Application budgets for NIH R21 grants are: \$275,000 in direct costs over a two-year project period, with a maximum of \$200,000 in direct costs in any given year. The maximum project period is two years.

Faculty of Medicine and Health Sciences
Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)
009 Kth Floor, Teaching Block, Tygerberg Campus.

Enquiries: fmhsgmo@sun.ac.za

Add “Interest in NIH opportunity” in the subject line.

Add the notice number with hyperlink in the text of the email.